Most Shorted Stocks
CRNX is part of our most shorted stocks screen list, indicating it has a high short interest.
CRINETICS PHARMACEUTICALS IN (CRNX) Stock Price & Overview
NASDAQ:CRNX • US22663K1079
Current stock price
38.44 USD
+0.29 (+0.76%)
At close:
38.44 USD
0 (0%)
After Hours:
The current stock price of CRNX is 38.44 USD. Today CRNX is up by 0.76%. In the past month the price increased by 5.84%. In the past year, price increased by 13.86%.
CRNX Key Statistics
52-Week Range25.83 - 57.99
Current CRNX stock price positioned within its 52-week range.
1-Month Range35.81 - 41.325
Current CRNX stock price positioned within its 1-month range.
- Market Cap
- 4.025B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.94
- Dividend Yield
- N/A
CRNX Stock Performance
Today
+0.76%
1 Week
-1.69%
1 Month
+5.84%
3 Months
-23.03%
Longer-term
6 Months -11.63%
1 Year +13.86%
2 Years -12.28%
3 Years +96.72%
5 Years +122.07%
10 Years N/A
CRNX Stock Chart
CRNX Stock Screens
CRNX currently appears in the following ChartMill screener lists.
CRNX Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CRNX. When comparing the yearly performance of all stocks, CRNX is a bad performer in the overall market: 74.22% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
CRNX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to CRNX. No worries on liquidiy or solvency for CRNX as it has an excellent financial health rating, but there are worries on the profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
CRNX Earnings
On February 26, 2026 CRNX reported an EPS of -1.29 and a revenue of 6.16M. The company beat EPS expectations (7.51% surprise) and beat revenue expectations (27.48% surprise).
Next Earnings DateMay 7, 2026
Last Earnings DateFeb 26, 2026
PeriodQ4 / 2025
EPS Reported-$1.29
Revenue Reported6.161M
EPS Surprise 7.51%
Revenue Surprise 27.48%
CRNX Forecast & Estimates
22 analysts have analysed CRNX and the average price target is 85.75 USD. This implies a price increase of 123.08% is expected in the next year compared to the current price of 38.44.
For the next year, analysts expect an EPS growth of -1.52% and a revenue growth 878.22% for CRNX
Analysts
Analysts84.55
Price Target85.75 (123.07%)
EPS Next Y-1.52%
Revenue Next Year878.22%
CRNX Index Membership
CRNX is currently included in the following stock indexes tracked on ChartMill.
CRNX Financial Highlights
Over the last trailing twelve months CRNX reported a non-GAAP Earnings per Share(EPS) of -4.94. The EPS decreased by -33.15% compared to the year before.
Income Statements
Revenue(TTM)7.70M
Net Income(TTM)-465.32M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -41.32% | ||
| ROE | -46.9% | ||
| Debt/Equity | 0 |
Chartmill High Growth Momentum
EPS Q2Q%-46.59%
Sales Q2Q%N/A
EPS 1Y (TTM)-33.15%
Revenue 1Y (TTM)640.71%
CRNX Ownership
Ownership
Inst Owners109.19%
Shares104.71M
Float101.64M
Ins Owners1.66%
Short Float %12.59%
Short Ratio11.86
CRNX Industry Overview
CRNX operates in the Pharmaceuticals sub-industry within the Health Care sector. This group contains 135 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Strength Score
66/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
Industry Growth Score
16/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
35%
Outperformed 35% of sub-industries
3 Month Rank
49%
Outperformed 49% of sub-industries
6 Month Rank
37%
Outperformed 37% of sub-industries
Industry Fundamentals & Breadth
- Members
- 135
- New Highs
- 3.7%
- New Lows
- 4.4%
- Average ROE
- 50.6%
- Average Profit Margin
- 27.8%
- Average Operating Margin
- 37.5%
- Average P/E
- 25.0
- Average Fwd P/E
- 19.7
- Average Debt/Equity
- 1.2
CRNX Competitors/Peers
The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 24.34 | 825.773B | ||
| JNJ | JOHNSON & JOHNSON | 17.92 | 548.657B | ||
| MRK | MERCK & CO. INC. | 21.79 | 271.761B | ||
| PFE | PFIZER INC | 8.79 | 150.628B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.1 | 118.952B | ||
| ZTS | ZOETIS INC | 16.09 | 49.054B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.58 | 28.582B | ||
| VTRS | VIATRIS INC | 6 | 17.257B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 20.72 | 11.061B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 9.463B | ||
| TERN | TERNS PHARMACEUTICALS INC | N/A | 6.11B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.955B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.86 | 4.959B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CRNX
Company Profile
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California and currently employs 594 full-time employees. The company went IPO on 2018-07-18. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Company Info
IPO: 2018-07-18
CRINETICS PHARMACEUTICALS IN
6055 Lusk Blvd.
San Diego CALIFORNIA 92121 US
CEO: R. Scott Struthers
Employees: 594
Phone: 18584506464
CRINETICS PHARMACEUTICALS IN / CRNX FAQ
What does CRINETICS PHARMACEUTICALS IN do?
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California and currently employs 594 full-time employees. The company went IPO on 2018-07-18. Its lead development candidate, PALSONIFY (paltusotine), is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Its second product candidate is Atumelnant, which is in clinical development for congenital adrenal hyperplasia (CAH) and patients with either Cushing's disease or Ectopic ACTH Syndrome (EAS). Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Can you provide the latest stock price for CRINETICS PHARMACEUTICALS IN?
The current stock price of CRNX is 38.44 USD. The price increased by 0.76% in the last trading session.
What is the dividend status of CRINETICS PHARMACEUTICALS IN?
CRNX does not pay a dividend.
How is the ChartMill rating for CRINETICS PHARMACEUTICALS IN?
CRNX has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the growth outlook for CRINETICS PHARMACEUTICALS IN?
The Revenue of CRINETICS PHARMACEUTICALS IN (CRNX) is expected to grow by 878.22% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the market capitalization of CRNX stock?
CRINETICS PHARMACEUTICALS IN (CRNX) has a market capitalization of 4.03B USD. This makes CRNX a Mid Cap stock.
What is the ownership structure of CRINETICS PHARMACEUTICALS IN (CRNX)?
You can find the ownership structure of CRINETICS PHARMACEUTICALS IN (CRNX) on the Ownership tab.